Fact checked by Nick BlackmerFact checked by Nick Blackmer The FDA has approved FluMist, a nasal spray flu vaccine, for ...

This application is for the study of a potential avian influenza combination therapy involving AIM's Ampligen and AstraZeneca (NASDAQ:AZN)'s FluMist, a nasal spray vaccine for seasonal influenza.

Earlier this week, AstraZeneca announced that the FDA is reviewing an application for its nasal spray flu vaccine FluMist, which would become the first self-administered flu vaccine available ...

This will be a follow-up study to a previous clinical trial at UAB, which indicated that intranasal delivery of Ampligen after the intranasal delivery of the FluMist seasonal influenza vaccine not ...

A small handful of intranasal flu vaccines are commercially available, such as FluMist, which came on the US market in 2003. Other flu vaccines and immunizations targeting other viruses have been in ...

Isadore Rosenfeld, MD The flu vaccine prevents a viral infection that hospitalizes 200 thousand people in this country every year and kills 36 thousand. We now know that everybody really should ...

a Chikungunya vaccine and which travelers should receive it to prevent severe, prolonged joint pain; which flu shots should be recommended and how FluMist should be given; protection for infants ...

Expert Rev Vaccines. 2012;11(5):547-560. In summary, despite some promising clinical trials and successful preclinical studies, no pulmonary influenza vaccines are available. Effective inhaler ...

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central ...